Shattuck Labs surged 14.29% intraday, driven by HC Wainwright & Co. upgrading its stock rating to Buy with a $6 target price effective December 1, 2025. The company specializes in developing therapies for inflammatory bowel disease and immune disorders, with its core project being the novel death receptor 3 antagonist SL-325 in the tumor necrosis factor receptor therapy area.
Comments
No comments yet